Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
Taylor and Francis
2016
|